Celldex Therapeutics Inc (NASDAQ: CLDX) is -40.26% lower on its value in year-to-date trading and has touched a low of $14.40 and a high of $47.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CLDX stock was last observed hovering at around $21.21 in the last trading session, with the day’s gains setting it 996388.79%.
Currently trading at $996410.0, the stock is 6.67% and 9.27% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.64 million and changing 4.24% at the moment leaves the stock -7.86% off its SMA200. CLDX registered -12.50% loss for a year compared to 6-month loss of -12.92%. The firm has a 50-day simple moving average (SMA 50) of $20.2346 and a 200-day simple moving average (SMA200) of $23.99635.
The stock witnessed a 10.72% gain in the last 1 month and extending the period to 3 months gives it a 31.22%, and is 3.03% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.12% over the week and 6.75% over the month.
Celldex Therapeutics Inc (CLDX) has around 186 employees, a market worth around $1.47B and $7.56M in sales. Profit margin for the company is -2366.07%. Distance from 52-week low is 53.54% and -52.96% from its 52-week high. The company has generated returns on investments over the last 12 months (-25.37%).
The EPS is expected to shrink by -40.83% this year
248.0 institutions hold shares in Celldex Therapeutics Inc (CLDX), with institutional investors hold 113.48% of the company’s shares. The shares outstanding are 66.38M, and float is at 64.51M with Short Float at 12.14%. Institutions hold 113.13% of the Float.
The top institutional shareholder in the company is WELLINGTON MANAGEMENT GROUP LLP with over 8.08 million shares valued at $298.89 million. The investor’s holdings represent 12.2328 of the CLDX Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 7.83 million shares valued at $289.76 million to account for 11.859 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 4.69 million shares representing 7.1052 and valued at over $173.61 million, while VANGUARD GROUP INC holds 5.6636 of the shares totaling 3.74 million with a market value of $138.38 million.
Celldex Therapeutics Inc (CLDX) Insider Activity
The most recent transaction is an insider purchase by Marucci Anthony S, the company’s PRESIDENT & CEO. SEC filings show that Marucci Anthony S bought 11,500 shares of the company’s common stock on Nov 11 ’24 at a price of $26.82 per share for a total of $0.31 million. Following the purchase, the insider now owns 40284.0 shares.
